Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Commercial Insight: Cancer Targeted Therapies and Immunotherapies' |
|
|
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
Apr 2008 | £7,210 | 100% |
| Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
Apr 2008 | £7,210 | 96% |
| Lung Cancer Vaccines and Therapeutic Antibodies | Oct 2011 | £1,490 | 94% |
| Pipeline Insight: Cancer Overview Gastrointestinal, Skin, Sarcomas |
Jan 2009 | £7,210 | 93% |
| Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
Dec 2006 | £1,600 | 92% |
| Prostate and Breast Cancer New Treatments & Developmental Progress |
Mar 2007 | £1,960 | 91% |
| Breast Cancer Therapeutic And Competitive Insights |
Feb 2007 | £1,295 | 90% |
| Pipeline Insight: Therapeutic Cancer Vaccines A turbulent path from bench to bedside |
Dec 2006 | £7,210 | 90% |
| Top 7 Cancer Indications Therapeutic & Competitive Insights |
Jan 2007 | £5,770 | 90% |
| Stakeholder Opinions: Bladder Cancer New drugs needed to challenge ineffective 20year old drugs | Nov 2008 | £2,405 | 89% |
| Hematological Cancers - A Therapeutic & Competitive Insight | Oct 2006 | £2,450 | 89% |
| Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
Apr 2006 | £1,900 | 88% |
| Lymphoma A Therapeutic & Competitive Insight |
May 2006 | £1,620 | 87% |
| Pipeline Insight: Colorectal Cancer Growing trend towards personalized medicine |
Oct 2009 | £7,210 | 86% |
| Pipeline Insight: Therapeutic Cancer Vaccines Prospect of first approval set to reinvigorate interest from major companies |
Dec 2009 | £7,210 | 83% |
| Lung Cancer Vaccines Pipeline, Strategies and Clinical |
Oct 2011 | £950 | 83% |
| Lung Cancer Therapeutic Antibodies Pipeline, Strategies and Clinical |
Oct 2011 | £750 | 82% |
| Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs Healthcare |
Mar 2009 | £2,405 | 80% |
| New Trends in Preventive and Therapeutic Vaccines - Overview R&D Activities and Commercial Prospects |
Oct 2011 | £1,580 | 78% |
| ASCO 2009: Significant Developments in Context | Jul 2009 | £595 | 75% |
- Results 1 - 20 of 20
-
-
- 1
-
-
